Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 67%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is expected to have a positive outlook due to their promising assets in solid tumor treatment, projected peak revenues of $6.8B from their leading BTK inhibitor, and upcoming catalysts such as potential approvals and data updates. Additionally, their deprioritization of early-stage programs and updated valuation, along with highly anticipated updates on their CDK4i, GPC3, and B7-H4 programs, further reinforce a strong outlook for the company.

Bears say

BeOne Medicines is a holding company with a negative outlook due to concerns over sustainability issues such as green manufacturing and drug pricing, as well as a lack of diversity in the management team and clinical trial data transparency. Despite being a leading player in the CLL market and having a strong revenue stream, the company's potential for long-term value creation and upside is uncertain due to the potential challenges in their pipeline and R&D execution. These factors could hinder the company's growth and profitability, leading to a negative outlook for the stock.

BeiGene Ltd (ONC) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 67% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 12 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Jun 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $387, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $387, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.